- Home
- TEAF vs SCLX Comparison
TEAF vs SCLX Comparison
Compare TEAF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- SCLX
- Stock Information
- Founded
- TEAF 2017
- SCLX 2011
- Country
- TEAF United States
- SCLX United States
- Employees
- TEAF N/A
- SCLX N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- SCLX Health Care
- Exchange
- TEAF Nasdaq
- SCLX Nasdaq
- Market Cap
- TEAF 173.4M
- SCLX 143.6M
- IPO Year
- TEAF N/A
- SCLX N/A
- Fundamental
- Price
- TEAF $13.26
- SCLX $0.95
- Analyst Decision
- TEAF
- SCLX Strong Buy
- Analyst Count
- TEAF 0
- SCLX 3
- Target Price
- TEAF N/A
- SCLX $11.33
- AVG Volume (30 Days)
- TEAF 56.1K
- SCLX 184.3K
- Earning Date
- TEAF 01-01-0001
- SCLX 11-12-2024
- Dividend Yield
- TEAF 9.20%
- SCLX N/A
- EPS Growth
- TEAF N/A
- SCLX N/A
- EPS
- TEAF N/A
- SCLX N/A
- Revenue
- TEAF N/A
- SCLX $50,833,000.00
- Revenue This Year
- TEAF N/A
- SCLX $34.42
- Revenue Next Year
- TEAF N/A
- SCLX $12.77
- P/E Ratio
- TEAF N/A
- SCLX N/A
- Revenue Growth
- TEAF N/A
- SCLX 9.41
- 52 Week Low
- TEAF $11.11
- SCLX $0.73
- 52 Week High
- TEAF $13.30
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- TEAF 71.96
- SCLX 51.50
- Support Level
- TEAF $12.97
- SCLX $0.77
- Resistance Level
- TEAF $13.25
- SCLX $1.07
- Average True Range (ATR)
- TEAF 0.10
- SCLX 0.09
- MACD
- TEAF -0.01
- SCLX 0.02
- Stochastic Oscillator
- TEAF 100.00
- SCLX 56.83
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.